PrLZ/PC-1 is a newly identified, prostate-specific and androgen-inducible gene. Our previous study showed that PrLZ can enhance the proliferation and invasive capability of LNCaP cells, contributing to the development of prostate cancer. However, its potential role in androgen-independent processes remains elusive. In this study, we showed that PrLZ enhanced in vitro growth and colony formation of prostate cancer cells on androgen deprivation as well as tumorigenicity in castrated nude mice. In addition, PrLZ stabilized mitochondrial transmembrane potential, prevented release of cytochrome c from mitochondria to cytoplasm, and inhibited intrinsic apoptosis induced by androgen depletion. Mechanistically, PrLZ elevated the phosphorylation of Akt and Stat3 and upregulated Bcl-2 expression. Our data indicate that PrLZ protects prostate cancer cells from apoptosis and promotes tumor progression following androgen deprivation. In summary, we propose that PrLZ is a novel antiapoptotic gene that is specifically activated in prostate cancer cells escaping androgen deprivation may offer an appealing therapeutic target to prevent or treat advanced prostate malignancy. Cancer Res; 71(6); 2193-202. Ó2011 AACR.
Introduction
Prostate cancer is the most common malignancy and the second leading cause of cancer death among males in the United States (1) . Growth of prostate cancer in the early stage is androgen dependent, and tumor cells undergo apoptosis on androgen depletion, forming the basis for androgen ablation therapy (2) . However, almost all patients will relapse with hormone-refractory disease due to the outgrowth of androgen-independent cancer cells (2, 3) . In this stage, the ratio of proliferation to apoptosis is unbalanced and cells are more resistant to apoptosis (4) , leading to failure of androgen ablation therapy and leaving patients with fewer therapeutic options. Until now, the detailed apoptosis-regulating mechanisms in prostate cancer cells resistant to androgen ablation therapy are still not clear.
The established LNCaP/C4-2 cell models mimic the clinical progression of prostate cancer (5) . LNCaP is androgendependent, nonmetastatic, and weakly tumorigenic, whereas its lineage-derived subline C4-2, obtained from tumor-stoma interaction, possesses the capabilities of androgen-independent growth and distant organ metastasis (6) . These 2 cell lines constitute an ideal experimental model system to explore the genetic and/or epigenetic differences between androgendependent and androgen-independent prostate cancer cells.
PrLZ, also known as PC-1, was first identified from 1,500 arrayed genes using cDNA differential expression microarray in LNCaP and C4-2 cells (7) . Compared with the low expression in LNCaP cells, PrLZ was distinctively upregulated in C4-2 cells. It localizes to human chromosome 8q21.1, one of the most amplified regions in prostate cancer (8, 9) . PrLZ belongs to the tumor protein D52 (TPD52) family, which is mainly associated with the proliferation and progression of tumors (10) . Unlike the extensive expression of TPD52 in many tumor tissues and cell lines, multiple tissue expression assays showed that PrLZ was predominantly expressed in prostate, with only minimal expression in the gastrointestinal tract and other secretory glandular tissues (7) . Immunohistochemical stains revealed that PrLZ was more highly expressed in high-grade prostatic intraepithelial neoplasia (PIN) and prostate cancer than in normal prostate or benign prostatic hyperplasia (BPH) (7) . Notably, intense staining of PrLZ was limited to malignant cells, but not neighboring unaffected or normal cells (7), indicating its direct relationship to carcinogenesis and tumor progression in prostate cancer.
Our previous research showed that PrLZ expression was associated with the proliferation and invasion of prostate cancer cells (11, 12) , which is consistent with other reports (13, 14) . To elucidate the potential role and mechanism of PrLZ in the progression from androgen-dependent to androgen-independent prostate cancer, we established the gain-offunction LNCaP cell model using PrLZ expression vector and the loss-of-function C4-2 cell model using PrLZ-specific microRNA (miRNA) vector. Our data suggested that PrLZ enhanced the in vitro and in vivo growth and tumorigenicity of prostate cancer cells in response to androgen deprivation. PrLZ also protected androgen-sensitive prostate cancer cells from intrinsic apoptosis following the deprivation of androgen via enhancement of Akt and Stat3 phosphorylation and upregulation of Bcl-2. Taken together, PrLZ seems to be a critical factor in promoting androgen-independent survival and progression of prostate cancer.
Materials and Methods

Cells and reagents
Human prostate cancer LNCaP and C4-2 cells were previously reported (5) Stable PrLZ-overexpressing sublines (i.e., LNCaP/PrLZ) and empty vector control (i.e., LNCaP/EV) subline were established as previously described (11) . PrLZ-specific miRNAexpressing plasmid pcDNA6.2-GW/EmGFP-miPrLZ and siRNA for Stat3 or Bcl-2 were designed and synthesized by Invitrogen. Sequence of miRNA or siRNA used in this study were as follows: miRNA for PrLZ forward 5 0 -TGC TGT TTG CAA GTT CTC TTC TTA GCG TTT TGG CCA CTG ACT GAC GCT AAG AAG AAC TTG CAAA-3 0 and reverse 5 0 -CCT GTT TGC AAG TTC TTC TTA GCG TCA GTC AGT GGC CAA AAC GCT AAG AAG AGA ACT TGC AAAC-3 0 ; siRNA for Stat3 sense 5 0 -GAA GCA GCA GAU GGA GCTT-3 0 and antisense 5 0 -GCU CCA UCU GCU GCU UCTT-3 0 ; siRNA for Bcl-2 sense 5 0 -UGA CUG AGU ACC UGA ACC GTT-3 0 and antisense 5 0 -CGG UUC AGG UAC UCA GUC ATC-3 0 . Transfection using Lipofectamine 2000 reagent (Invitrogen) was carried out according to the manufacturer's protocol. For obtaining stable transfectants, transfected cells were selected in complete growth medium containing 3.0 mg/mL Blasticidin (Invitrogen). All clones selected were further verified by Western blot.
MTT assay
Cell growth rate was determined by MTT proliferation assay as in our previous study (15) . Briefly, after cells were seeded in 96-well plates in medium containing C/D FBS, MTT (final concentration 0.5 mg/mL; Sigma) was added, incubated for 4 hours, and dimethyl sulfoxide (DMSO) was then added to solubilize the formazan crystals. The absorbance (OD) was measured at 590 nm using the Microplate Autoreader (BioTek Instruments). Independent experiments were repeated in triplicate.
Colony formation assay
A total of 1,000 cells per well of single-cell suspension were seeded in 6-well plates. After 24 hours, medium was replaced with fresh medium containing C/D FBS and plates were incubated at 37 C with 5% CO 2 in a humidified incubator for 14 days; fresh medium was added every 4 days. The plates were then washed with ice-cold PBS, fixed with 4% paraformaldehyde, stained in crystal violet solution for 15 minutes at room temperature, and washed with distilled water until no color was evident in the rinse. Plates were dried in air and the colony numbers were counted.
Apoptosis and mitochondrial transmembrane potential assay
Cells were plated in medium containing C/D FBS for 72 hours and then harvested and washed with PBS. Apoptosis kit (Invitrogen) containing Annexin V-FITC and propidium iodide (PI) were used to determine cell apoptosis. Mitochondrial transmembrane potential (DY m ) was determined by JC-1 staining. Data were collected by flow cytometric analysis using FACS Calibur (Becton Dickinson). For each assay, 3 independent experiments were conducted.
Western blot analysis
The whole cell lysate was prepared using RIPA buffer containing proteinase inhibitors. The cytosol/mitochondria fractionation was prepared using a mitochondria extraction kit (Runtai Biotech). An equal amount of lysates (30 mg) was separated by 12% SDS-PAGE and transferred to nitrocellulose membranes. The membranes were initially blocked with 5% skim milk in TBS for 1 hour at room temperature, followed by incubation with primary antibodies at 4 C overnight. After washing with TBST buffer, membranes were incubated with secondary antibodies coupled with horseradish peroxidase for 1 hour at room temperature, and protein signal was then detected using the ECL chemiluminescent detection system (Amersham). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a loading control.
Xenograft animal model
Six-to 8-week-old nude athymic BALB/c male mice were used to determine the in vivo tumor take and tumor growth rate. Cells (5 Â 10 6 ) were suspended in 200 mL serum-free RPMI 1640 containing Matrigel (1:1, v/v; BD Biosciences) and injected subcutaneously (s.c.) into both flanks of mice using a 27-gauge insulin syringe. Mice bearing tumors were castrated 4 weeks after cell injection. Tumor volumes were measured weekly for 8 weeks. Then the primary tumors were removed, fixed in 4% paraformaldehyde, embedded in paraffin, sectioned, and stained with hematoxylin and eosin (H&E). Immunohistochemical staining was carried out as described previously (16) , and results were quantified using software of Image-Pro 6.3.
Statistical analysis
All data analyses were done by software of SPSS13.0 for Windows. P < 0.05 was regarded as the threshold value for statistical significance.
Results
Establishment of PrLZ-overexpressing and -knockdown prostate cancer cell lines
Stable PrLZ-overexpressing (i.e., LNCaP/PrLZ) cells were established and reported in our previous studies (11) . Three LNCaP/PrLZ sublines, LNCaP/PrLZ1, LNCaP/PrLZ2, and LNCaP/PrLZ3, exhibited elevated PrLZ protein expression (Fig. 1A) ; 2 of them were randomly chosen for future study. To establish PrLZ knockdown in C4-2 cells, PrLZ-specific miRNA-expressing vector or control vector was transfected into C4-2 cells, followed by selection with Blasticidin (3 mg/ mL) for 4 weeks and then individual Blasticidin-resistant clones were isolated. Three clones with decreased expression of PrLZ determined by Western blot were designated as C4-2/ miPrLZ1, C4-2/miPrLZ2, and C4-2/miPrLZ3 (Fig. 1B) ; 2 of them were chosen for future study. The empty vector-transfected control cells were designated as C4-2/EV.
PrLZ promotes in vitro and in vivo growth in prostate cancer cells following androgen depletion
Previously, we showed that PrLZ enhanced the in vitro growth capability of LNCaP cells (11) . In this study, we further characterized the effect of PrLZ on the in vitro growth of prostate cancer cells under androgen deprivation conditions (i.e., medium containing C/D FBS). As shown in Figure 2A , LNCaP/PrLZ cells exhibited an accelerated growth profile compared with parental LNCaP or control LNCaP/EV cells, which displayed no significant growth over 6 days of androgen depletion. In contrast, both C4-2 and C4-2/EV cells were able to grow under androgen deprivation conditions, whereas PrLZ-knockdown C4-2/miPrLZ cells displayed dramatically decreased growth rates (Fig. 2B) .
Next, we determined the colony formation capacity of prostate cancer cells with or without exogenous PrLZ expression under androgen deprivation condition. We found that the parental androgen-dependent LNCaP and control LNCaP/EV cells formed a similar number of colonies, which was significantly lower than that formed by the LNCaP/PrLZ cells (P < 0.05; Fig. 2C ). On the contrary, both C4-2 and C4-2/EV cells formed significantly more colonies than C4-2/miPrLZ cells under androgen deprivation condition (P < 0.05; Fig. 2D ).
In addition, we also determined in vivo tumor growth and tumor take of these cells in nude mice. Similar to our previous work (11), data from s.c. model indicated that ectopic PrLZ expression facilitated tumor take rate and accelerated tumor growth in LNCaP/PrLZ cells; detectable tumors were observed within as few as 10 days after injection. In contrast, parental LNCaP cells could not form tumors until at least 3 weeks after injection. In addition, the growth rate of parental LNCaP cells was much slower than LNCaP/PrLZ cells (P < 0.001; Fig. 3A and B). Similar results were observed in PrLZ-positive C4-2 cells, however, C4-2/miPrLZ cells did not form any detectable tumors. As we expected, when all the mice were castrated 4 weeks after cell injection, the parental LNCaP tumor displayed growth retardation whereas LNCaP/PrLZ and C4-2 tumors maintained a rapid growth rate in the xenograft mice model (Fig. 3A and B) . Histologic analysis indicated that tumors derived from LNCaP/PrLZ cells exhibited more blood vessels compared with parental LNCaP cells (Fig. 3C) .
PrLZ protects prostate cancer cells from apoptosis in response to androgen deprivation
Androgen deprivation can cause apoptosis in both normal and malignant prostate cells (17) . To investigate the role of PrLZ in apoptosis, cells were exposed to medium containing C/D FBS for 72 hours then the degree of apoptosis was determined. Our results showed that the percentage of apoptotic cells was significantly lower in LNCaP/PrLZ and C4-2 cells compared with parental LNCaP and C4-2/miPrLZ cells (P < 0.01; Fig. 4A, top) . These data indicated that PrLZ is able to inhibit cell apoptosis under androgen deprivation Figure 1 . Determination of PrLZ expression in stable transfected cells. A, the expression of PrLZ in parental LNCaP, control LNCaP/EV, and PrLZ-overexpressing LNCaP/PrLZ cells was determined using Western blot with GAPDH as an internal control. B, the expression of PrLZ in parental C4-2, control C4-2/EV, and PrLZ miRNA-targeting C4-2/miPrLZ cells was determined using Western blot with GAPDH as an internal control.
condition. As the loss of mitochondrial transmembrane potential (DY m ) plays an important role in triggering apoptotic pathways, we measured the effect of PrLZ on DY m . Following androgen deprivation for 72 hours, consistent with the apoptosis data (Fig. 4A) , a significant loss of DY m was observed in LNCaP and C4-2/miPrLZ cells compared with PrLZ-overexpressing LNCaP/PrLZ and parental C4-2 cells, respectively (Fig. 4A, bottom) . These results indicated that PrLZ can stabilize mitochondria membrane in apoptotic events in response to androgen deprivation.
We further explored the effect of PrLZ on the apoptosis cascade under androgen deprivation condition. As shown in Figure 4B , mitochondrial cytochrome c levels in LNCaP, LNCaP/EV, and C4-2/miPrLZ cells decreased in response to androgen deprivation, whereas cytosolic cytochrome c levels became elevated, indicating that there was a increased release of cytochrome c from mitochondria to cytosol in these cells. Also, data (Fig. 4B ) from Western blot revealed that elevated expression of cleaved caspase-9, caspase-3, and PARP was detected in LNCaP, LNCaP/EV, and C4-2/miPrLZ cells following androgen deprivation. Only minimal levels of these cleaved proteins were detectable in LNCaP/PrLZ, parental C4-2, or control C4-2/EV cells, suggesting that PrLZ probably antagonizes the intrinsic apoptosis.
PrLZ elicits the phosphorylation of Akt and Stat3 and upregulates the expression of Bcl-2, Bcl-xL, Mcl-1, and VEGF Both Akt and Stat3 have been demonstrated to play a critical role in the malignancy, castration-resistance, and metastases of prostate cancer (18) (19) (20) . Therefore, we further determined the effect of PrLZ on their expression and activation/phosphorylation under androgen deprivation conditions. As shown in Figure 5A , PrLZ elicited the phosphorylation of Akt (Ser 473 ) and Stat3 (Tyr 705 ) in LNCaP/PrLZ cells whereas C4-2/miPrLZ cells displayed a decreased level compared with parental C4-2 cells. In addition, Bcl-2, Bcl-xL, and Mcl-1, downstream targets of Stat3 and potent antiapoptotic proteins, were also examined. As expected, their levels were increased in LNCaP/PrLZ and C4-2 cells relative to those in LNCaP and C4-2/miPrLZ cells respectively (Fig. 5A) .
In addition, immunohistochemistry was applied to determine the expression pattern of Stat3 and Bcl-2 in tumor specimens from nude mice. The results showed that the nuclear expression of Stat3 (activated Stat3) and Bcl-2 expression were significantly elevated in LNCaP/PrLZ and C4-2 tumors, whereas tumors derived from parental LNCaP cells exhibited cytoplasmic expression of Stat3 (inactivated Stat3) and low staining of Bcl-2 (Fig. 5B) . Furthermore, VEGF, a hallmark of angiogenesis, also elevated in tumors derived from LNCaP/PrLZ and C4-2 cells (Fig. 5B) . In addition, quantified analysis showed that parental LNCaP cells exhibited lower expression of nuclear Stat3, Bcl-2, and VEGF compared with LNCaP/PrLZ and C4-2 cells (Fig. 5C ).
Inactivation of Akt inhibits Stat3 phosphorylation in LNCaP/PrLZ and C4-2 cells
Previous findings indicated that cross-talk existed between JAK/Stat and PI3K/Akt signaling pathways (21) (22) (23) . In this study, cells were treated with LY 294002 (an inhibitor of PI3K) or Stattic (a Stat3 specific inhibitor). As shown in Figure 6A , both inhibitors abolished Akt or Stat3 phosphorylation respectively. Notably, LY 294002 treatment not only reduced Akt activation but also decreased Stat3 phosphorylation. However, when cells were exposed to Stattic, no changes in Akt phosphorylation were observed. These data indicate that Akt is an upstream regulator for Stat3.
Stat3/Bcl-2 signaling pathway mediated the antiapoptotic function of PrLZ
To further investigate the significance of Stat3 signaling in the antiapoptotic function of PrLZ following androgen deprivation in prostate cancer cells, we targeted Stat3 with either siRNA or Stattic. Notably, knockdown or inhibition of Stat3 led to apoptosis as well as loss of DY m in PrLZ-overexpressing LNCaP/PrLZ cells and C4-2 cells with high endogenous PrLZ expression following androgen withdrawal (Fig. 6B) . In addition, Bcl-2 protein was also inhibited by knocking down Stat3 (Fig. 6C) . Furthermore, when knocking down Bcl-2 in LNCaP/ PrLZ and C4-2 cells, both increased apoptosis and loss of DY m were observed regardless of the presence of PrLZ and Stat3 phosphorylation (Fig. 6B) . These alterations were concomitant with elevation of cleaved caspase-9, caspase-3, and PARP detected by Western blot (Fig. 6C) .
Discussion
PrLZ is a newly identified, prostate-specific, and androgeninducible gene (7) . Because it is upregulated in androgenresistant C4-2 cells and overexpressed in human prostate cancer, we hypothesized that PrLZ may play a role in the outgrowth of androgen-independent prostate cancer. To test this hypothesis, we determined the effect of PrLZ on the growth capability of prostate cancer cells under androgen deprivation in both androgen-sensitive LNCaP cells and androgen-independent C4-2 cells. Several lines of evidence from our study showed that PrLZ is critical for the outgrowth of androgen-independent prostate cancer cells. First, PrLZ overexpression promoted the growth of LNCaP cells in the absence of androgen, whereas PrLZ-knockdown cells exhibited a dramatically reduced growth in C4-2 cells. Second, the colony formation assay demonstrated that cell transformation capability was enhanced with PrLZ overexpression in LNCaP/PrLZ cells but reduced in C4-2/miPrLZ cells. Third, consistent results were obtained from a xenograft animal model. Compared with parental LNCaP cells, LNCaP/PrLZ cells exhibited higher tumor take rate and accelerated tumor growth under androgen deprivation condition. Similarly, C4-2/miPrLZ cells failed to form any tumors compared with C4-2 cells. These in vitro and in vivo experiments clearly indicate that PrLZ is sufficient to drive androgen-independent growth in prostate cancer cells and is indispensable for the survival of androgen-independent C4-2 cells. Our data also suggest that PrLZ may play a critical role in regulating prostate cancer progression during androgendependent to androgen-independent conversion.
Accumulating data have shown that either JAK/Stat or PI3K/Akt signaling pathway are critical for cancer cell survival and metastasis (18-20, 24, 25) . On Stat activation, Stat proteins are phosphorylated to form either homodimers or heterodimers, and then translocated into nucleus where they can bind to their target gene promoter sequences and activate transcription (26) . Stat3, one of the key members of this family, has been shown to play a crucial role in prosurvival activities of prostate cancer cells (27, 28) . In addition, a recent study indicates that PrLZ overexpression can enhance Akt phosphorylation underlying the progression of prostate cancer (14) . In this study, we show that PrLZ could increase Stat3 phosphorylation mediated by activation of Akt, which is further demonstrated by rescue experiments showing that inhibition of PI3K by specific inhibitor could abolish both Akt and Stat3 phosphorylation in PrLZ-expressing cells, whereas inhibition of Stat3 activation could not change Akt phosphorylation. Based on these data, we conclude that Akt is an upstream regulator for Stat3 in PrLZ mediated antiapoptotic effects. In addition, it has been reported that interleukin-6 (IL-6) or epidermal growth factor (EGF) increases Stat3 phosphorylation and regulates LNCaP cells growth (29) (30) (31) (32) (33) . We examined whether elevated IL-6 or EGF can be detected in PrLZ-expressing cells. However, we failed to show that PrLZmediated Stat3 activation goes through IL-6 or EGF regulation loop in these cells (Supplementary Fig. S1 ).
It is known that Bcl-2, Bcl-xL, Mcl-1, and VEGF are all the downstream target genes of Stat3 (29, 34) . Both Bcl-2 and Bcl-xL localize on the outer mitochondrial membrane (35) and are able to stabilize the mitochondrial membrane potential, maintain mitochondrial permeability, and prevent the release of cytochrome c from mitochondrial to cytoplasm on repressed apoptosis (36, 37) . In PrLZ-overexpressed prostate cancer cells, we have observed a stabilization of mitochondrial transmembrane potential along with the induction of Bcl-2, Bcl-xL, and Mcl-1 in the condition of androgen deletion. In contrast, both loss of mitochondrial transmembrane potential and decreased expression of Bcl-2, Bcl-xL, and Mcl-1 were observed in PrLZ knocked down prostate cancer cells in the condition of androgen deletion. In addition, when Stat3 was knocked down using siRNA or inactivated by inhibitor, Bcl-2 was downregulated accordingly. Also, increased apoptosis and loss of mitochondrial transmembrane potential were observed. Taken together, these data provide supporting evidence that PrLZ play the survival roles in prostate cancer cells on androgen-independent progression (38, 39) .
In summary, our data showed that overexpression of PrLZ could protect prostate cancer cells from apoptosis induced by androgen deprivation, which is mediated by the activation of Stat3/Bcl-2 signaling pathway. Thus, PrLZ is a potential factor in the outgrowth of androgen-independent prostate cancer. Considering its prostate specificity and upregulation Figure 6 . Analyses of the pathways associated with antiapoptotic function of PrLZ. A, cells were treated with either LY 294002 (30 mmol/L) or Stattic (20 mmol/L) for 1 hour and cell lysates were subjected to Western blot for determining total or phosphorylated Akt and Stat3 levels. B and C, LNCaP/PrLZ and C4-2 cells were treated with siRNA specific to Stat3 or Bcl-2 or Stattic, underwent androgen withdrawal for 72 hours, and then were analyzed for apoptosis and mitochondrial transmembrane potential (DY m ) by flow cytometry (*, P < 0.01; **, P < 0.05). D, Western blot analysis of apoptosis-associated proteins.
in androgen-independent prostate cancer, PrLZ could be an attractive therapeutic target for prostate cancer therapy.
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